Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?

Renal Failure

Volumn 29, Issue 4, 2007, Pages 423-426

  Sav, Tansu ^a,b   Tokgoz, Bulent ^a   Sipahioglu, Murat Hayri ^a   Deveci, Murat ^a   Sari, Ismail ^a   Oymak, Oktay ^a   Utas, Cengiz ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Allergy; Anemia; End stage renal disease; Iron replacement

Indexed keywords

FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BRONCHOSPASM; CELLULITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEMALE; FEVER; FLUSHING; HEADACHE; HEART ARREST; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PARESTHESIA; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWELLING; SYNCOPE; THORAX PAIN; URTICARIA; VOMITING; WEAKNESS; WHEEZING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, INTRA-ARTERIAL; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 34248592639     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701278208     Document Type: Article

References (23)

1. Dahdah K, Patrie JT, Bolton WK. Intravenous iron dextran treatment in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000 Oct;36(4):775-782.
2. Nissenson AR. National cooperative rHuEPO study in patients with chronic renal failure: A phase IV multicenter study. Am J Kidney Dis. 1991;18:24-33.
3. Kleiner MJ, Van Wyck DB, Kaupke CJ, Kirlin LF. The role of iron and other factors in patients unresponsive to EPO therapy. Semin Dial. 1994;7:288-292.
4. Akmal M, Sawelson S, Karubian F, Gadallah M. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure, or receiving dialytic therapy. Clin Nephrol. 1994;42:198-202.
5. Barth RH. Iron metabolism in end-stage renal disease. Semin Dial. 1999;12:224-230.
6. Wingard RL, Parke RA, Ismail N, Hakim R. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25:433-439.
7. Van Wyck DB. Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis. 1989;14:9-13.
8. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron suplementation for the treatment of anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-238.
9. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoetin. Clin Nephrol. 1997;48:34-40.
10. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000;36(1):88-97.
11. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20(7):1443-1449. E-pub 2005 Apr 26.
12. Walters BA, Van Wyck DB. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant. 2005;20(7):1438-1442. E-pub 2005 Apr 19.
13. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int. 2001;21(3):290-295.
14. Basic-Jukic N, Kes P, Juric I. Principles of iron therapy in hemodialysis patients. Acta Med Croatica. 2006 Dec;60(5):457-462.
15. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a two-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis. 2005;46(2):283-289.
16. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001;38(5):988-991.
17. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA. 1980;243:1726-1731.
18. Burns DL, Pomposelli JJ. Toxicity of parenteral iron dekstran therapy. Kidney Int Suppl. 1999;69:119-124.
19. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 2000;35:360-361.
20. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006 Feb;21(2):378-382. E-pub 2005 Nov 11.
21. McCarthy JT, Regnier CE, Loebertmann CL, Bergstralh EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products. Am J Nephrol. 2000;20:455-462.
22. Roe DJ, Harford AM, Zager PG, Wiltbank TB, Kirlin L, Della Vale AM, Van Wyck DB. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. Am Jm Kidney Dis. 1996;28:855-860.
23. Novey HS, Pahl M, Haydik I, Vaziri ND. Immunolojic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy. 1994;72:224-228.